This paper examines relationships between metrics of visit-to-visit variability (VVV) of blood pressure (BP) to determine which metrics should be calculated in studies of the association of VVV with health outcomes. We examined correlation and agreement between quintiles for standard deviation (s.d.), standard deviation independent of the mean (SDIM), coefficient of variation (CV), successive variation (SV), average real variability (ARV), range, maximum, peak size and trough size of systolic BP in the Trial of Preventing Hypertension placebo arm (n ¼ 288). The average age of participants was 48 years. Mean systolic BP was 133.5 mm Hg. VVV metrics were all significantly correlated (Po0.001). Correlations between s.d., SDIM, CV and range and between ARV and SV wereX0.90. Kappa statistics between quintiles of SD, SDIM, CV and range and between ARV and SV were X0.80. In studies of the relationship of VVV with health outcomes, we recommend reporting results for one of the metrics of overall variability (s.d., SDIM, CV), one of the metrics of variability between consecutive visits (SV, ARV), and one or more of the metrics of extreme values at a single visit (maximum, peak size, trough size).
INTRODUCTION
In several recent studies, visit-to-visit variability (VVV) of blood pressure (BP) has been associated with the incidence of stroke, cardiovascular disease (CVD) and all-cause mortality in the general population and in-patient populations with a history of stroke or transient ischemic attack, diabetes or end-stage renal disease. [1] [2] [3] [4] [5] [6] [7] [8] In some populations, VVV of systolic BP (SBP) has been more strongly associated with these outcomes than mean SBP. 2 As this area of research has grown, several metrics for quantifying VVV have been proposed. These include standard deviation (s.d.), standard deviation independent of the mean (SDIM), coefficient of variation (CV), successive variation (SV), average real variability (ARV), range, maximum, peak size, and trough size. These metrics may contain redundant information. s.d., SDIM and CV account for the total variability around the mean BP across visits; SV and ARV measure the differences in BP between consecutive visits; and range, maximum, peak size and trough size are influenced by extreme observations.
Authors have reported the associations of several VVV metrics with outcomes within a single population. 1, 2, 5 Given the potential interrelationship between VVV metrics, it is not clear to what extent presenting the associations for multiple metrics adds to the understanding of the relationship of VVV with outcomes. If correlations between VVV metrics are very high, then they largely convey the same information and investigators do not need to report the association between multiple VVV metrics and outcomes.
Previous studies have reported high correlations between VVV metrics. 5, 6 For example in the Women's Health Initiative, correlations of s.d. with SDIM and CV were X0.90. 6 However, prior studies primarily focused on the VVV-outcome association and the relationships between VVV metrics were not presented in detail. In order to better understand the value of reporting the association between multiple VVV metrics and CVD risk, we examined the interrelationships between VVV metrics among participants in the placebo arm of the Trial of Preventing Hypertension (TROPHY).
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MATERIALS AND METHODS
Study population
The TROPHY design and results have been described previously. 9, 10 Men and women of 30-65 years of age with high-normal BP (average SBP/ diastolic BP (DBP) of 130-139/p89 mm Hg or p139/85-89 mm Hg over three baseline visits) were randomized to 16 mg per day of candesartan (n ¼ 391) or placebo (n ¼ 381). BP was measured every 1-3 months for up to 4 years. The primary end point was a composite of three visits with SBP X140 mm Hg or DBP X90 mm Hg; one visit with SBP X160 mm Hg or DBP X100 mm Hg; or target organ damage or other clinical reasons to start antihypertensive therapy as determined by the investigators. If a participant reached the end point, open-label antihypertensive treatment was begun. Treatment with metoprolol or hydrochlorothiazide was provided at no cost to participants. Other antihypertensive medications, with the exception of angiotensin-receptor blockers, could also be used. For this analysis, we included 288 participants randomized to placebo who completed the first seven post-baseline visits. Eighty-five of these participants reach the study end point before visit 7 and began openlabel antihypertensive therapy. In sensitivity analyses, we examined only the 203 individuals who were randomized to placebo and did not reach the study end point before visit 7. Institutional review boards at all participating centers approved the TROPHY protocol, and all participants provided written informed consent.
Measurement of BP and VVV
At each clinic visit BP was measured three times using an automated device (HEM-705CP, Omron Healthcare, Bannockburn, IL, USA) and three times using a manual device. The order of the automated and manual BP measurements and the specific manual BP measurement device used were not specified in the TROPHY protocol. We used the mean of the three manual BP measurements as the visit BP for our primary analysis and the mean of three automated BP measurements as the visit BP in secondary analyses. Because participants were required to have BP within a narrow range at the three baseline visits to be eligible for TROPHY, BP measurements from these visits were not used in any of the analyses. Prior studies have found associations of VVV of SBP with stroke, CVD and mortality, but VVV of DBP has not been associated with these outcomes. 1, 2 We have therefore focused on SBP in our primary analyses. VVV metrics are positively correlated with the number of visits used to calculate them, [11] [12] [13] so the same number of visits should be used to calculate VVV for all participants in a study. We used the first seven post-baseline visits to calculate VVV, because we view seven visits as a reasonable trade-off between precision in the estimation of VVV and the loss of participants that would occur if more visits were required. Additionally, several previous publications have used seven visits to calculate VVV. 2, 14, 15 We calculated intra-individual s.d., SDIM, CV, SV, ARV, range, maximum, peak size and trough size for SBP and DBP. SDIM was calculated to be proportional to SD= x a , where a was derived by fitting the curve SD ¼ k x a , x is the mean BP, and k and a are estimated from the data.
14 SV was calculated as
, and ARV was calculated as
1Þ where x i is a participant's BP at visit i and n is the number visits (n ¼ 7 for these analyses). The peak size was defined as the maximum BP minus the mean BP, and the trough size was defined as the mean minus the minimum BP. 14 
Statistical analysis
We first calculated means and s.d. or percentages of baseline characteristics of the TROPHY placebo group participants. We constructed scatter plots and computed Pearson correlations between each of the metrics of VVV of SBP. Because VVV is often categorized for analysis, we grouped participants into quintiles for each of the of VVV metrics. We calculated the agreement between quintiles of each metric, above that expected by chance, using weighted kappa statistics. We repeated these analyses for VVV of DBP. In sensitivity analyses, we conducted the analyses described above (1) with SBP measured as the mean of three automated readings per visit and (2) among TROPHY placebo group participants who did not initiate antihypertensive medication before post-baseline visit 7 (n ¼ 203). Analyses were conducted using SAS version 9.3 (Cary, NC) and R version 2.12.1 (Vienna, Austria).
RESULTS
The average age of the TROPHY participants was 48 years, 60% were men and 87% were white (Table 1) . Mean baseline SBP was 133.5 mm Hg and mean baseline DBP was 83.4 mm Hg. The average intra-individual s.d. of SBP across seven study visits was 6.8 mm Hg.
All of the VVV metrics were significantly correlated with each other (Figure 1 , Po0.001 for all comparisons). Correlation coefficients ranged from 0.38 between maximum and trough to 1.00 between SDIM and CV ( Table 2 ). Correlations between s.d., SDIM, CV and range and between ARV and SV were X0.90. Correlations of s.d., SDIM and CV with all other metrics, except maximum, were X0.75. Correlations of SV and ARV with all other metrics, except maximum, were X0.67.
All of the metrics showed higher agreement than would be expected by chance (Po0.001 for all comparisons; Table 3 ). Weighted kappa statistics between s.d., SDIM, CV and range and between ARV and SV were X0.80. Kappa statistics for quintiles of s.d., SDIM, CV and range compared with quintiles of all other metrics, except maximum, were X0.55. Kappa statistics for quintiles of SV and ARV compared with quintiles of all other metrics, except maximum, were X0.49.
The correlations and kappa statistics were similar when we used automated measurement of SBP and when we limited the analysis to the 203 participants who had not initiated antihypertensive therapy (data not shown). Correlations and kappa statistics between different metrics of VVV of DBP were similar to those described above for the metrics of VVV of SBP (Supplementary  Tables 1 and 2 ).
DISCUSSION
We found that intra-individual visit-to-visit s.d., SDIM and CV are tightly correlated with very high agreement when divided into quintiles. All three of these VVV metrics assess the variability around the mean SBP across visits. Similarly, ARV and SV, measures of the difference in SBP between consecutive visits, had a nearly perfect correlation and very high agreement. The relationships between range, maximum, peak size and trough size, which are influenced by extreme observations at individual visits, were more varied and not as strong. Range, for example, was more highly correlated with s.d., SDIM and CV than with maximum, peak size or trough size. These results indicate that the published VVV metrics provide substantially overlapping information. Our findings should be useful to other workers studying VVV, because the documented relationships between the metrics obviate the need for multiple redundant analyses.
Correlation coefficients, which range from À 1 to 1, reflect the linear association between two variables. The high correlations (X0.90) between some of the VVV metrics, particularly s.d., SDIM and CV and SV and ARV, reflect a nearly perfect overlap in the information conveyed. Kappa statistics, with a maximum value of 1, are a measure of agreement between categorical measurements accounting for the agreement that would be expected due to chance alone. Kappa statistics 40.80, as we observed between several of the VVV metrics, indicate 'almost perfect agreement.' 16 Maximum BP was only moderately correlated and showed only 'fair agreement' 16 with other VVV metrics. This may be because a high maximum BP could reflect either large fluctuations in BP leading to high VVV or high, but stable, mean BP leading to low VVV.
Given that s.d., SDIM and CV of BP convey the same information about the variability around the mean BP across visits, calculating Visit-to-visit variability metrics EB Levitan et al one of these metrics is sufficient to capture this element of variability. Similarly, SV and ARV of BP capture variability from one visit to the next, and calculating both does not add information.
On the other hand, maximum, peak size and trough size seem to convey different information about VVV of BP based on the moderate correlation and agreement between the metrics. Strong correlations between VVV metrics have been noted in previous studies. s.d. was highly correlated with SDIM (r ¼ 0.90) and CV (r ¼ 0.97) in the Women's Health Initiative, 6 but the correlations between other proposed VVV metrics were not reported. In a group of dialysis patients, VVV metrics were noted to be strongly correlated and to load on a single principal component, which suggests they are measuring the same underlying phenomenon; however, details were not provided on their interrelationships. 5 Associations of VVV with stroke, CVD and mortality have been similar when different metrics have been used to assess VVV. 1, 2, 5 For example, the hazard ratio for mortality was 1.50 (95% confidence interval 1.03-2.18) comparing the top to bottom tertile of SD of SBP and 1.49 (95% confidence interval 1.05-2.10) comparing the top to bottom tertile of CV of SBP in follow-up of the Third National Health And Nutrition Examination Survey (NHANESIII). 1 Most of the research on the relationship between VVV and CVD outcomes has included s.d., SDIM and/or CV as measures of VVV; ARV has also been reported to be associated with CVD in dialysis patients. 5 Within a population, similar associations across different VVV metrics would be expected if they were measuring the same or similar aspects of VVV. Our work extends these observations by detailing the interrelationships between the metrics in a population with highnormal BP.
Strengths of this study include repeated BP measurements at standardized time intervals using research protocols in a relatively healthy population and the examination of multiple metrics of VVV as both continuous and categorical variables. There are also several important weaknesses. Although no one in the population was on antihypertensive therapy at the beginning of the study, some participants initiated antihypertensive therapy in the period during which VVV was assessed. This could increase the observed VVV. Because of the study design, individuals with higher VVV could have been preferentially prescribed antihypertensive therapy. However, when we limited the analysis to participants who did not start antihypertensive therapy, results were not materially changed. The mean BP at baseline was constrained to a narrow range in this population, so the results may not be fully generalizable to populations with a wider range of BP values. In particular, the correlations of s.d. with SDIM and CV, which index s.d. to the mean BP, may be weaker when the mean BP has a larger range. Additionally, the maximum BP was constrained in Visit-to-visit variability metrics EB Levitan et al TROPHY because of the study protocol that required antihypertensive therapy initiation following high BP readings. Most important, our study showed that the VVV metrics were closely related and that examining all of them would not add information. However, we do not have a gold standard to suggest which metric or metrics are the best indicators of underlying BP variability and its relationship with future outcomes. Further research on this issue is needed. In summary, the VVV metrics investigated in the current study are related to each other, and some of the metrics such as s.d., SDIM and CV and ARV and SV provide largely redundant information. Calculating several metrics that capture the same aspect of VVV will not provide additional insight into the relationship with outcomes. In the absence of empirical evidence about their association with outcomes, we recommend calculating one of the metrics of overall variability (s.d., SDIM or CV), one of the metrics of variability between consecutive visits (SV or ARV), and one or more of the metrics of extreme values (maximum, peak size and/or trough size).
What is known about the topic
Visit-to-visit variability of blood pressure is associated with stroke, other cardiovascular diseases and mortality. In previous studies, the various metrics of visit-to-visit variability of blood pressure have been correlated, but the relationships have not been described in depth.
What this study adds
Correlations between visit-to-visit variability of blood pressure as assessed by standard deviation, standard deviation independent of the mean, coefficient of variation and range and between average real variability and successive variation were X0.90. Because they are largely redundant, it is not necessary to study all of the proposed metrics of visit-to-visit variability of blood pressure in order to capture the association between visit-to-visit variability of blood pressure and cardiovascular outcomes.
